Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

BACKGROUND: Indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27.5/15.6 µg) inhalation powder, a twice-daily, fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting antimuscarinic antagonist (LAMA), is indicated in the US for long-term maintenance treatment of airflow obstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopalan, Krithika, Bloudek, Lisa, Marvel, Jessica, Dembek, Carole, Kavati, Abhishek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276826/
https://www.ncbi.nlm.nih.gov/pubmed/30568438
http://dx.doi.org/10.2147/COPD.S177097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276826/
https://www.ncbi.nlm.nih.gov/pubmed/30568438
http://dx.doi.org/10.2147/COPD.S177097

Ejemplares similares